A second report on Levodopa.
D000547:Amantadine / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D002561:Cerebrovascular Disorders / Q000139:chemically induced; D004295:Dihydroxyphenylalanine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007024:Hypotension, Orthostatic / Q000139:chemically induced; D007880:Legislation, Drug; D009069:Movement Disorders / Q000139:chemically induced; D009325:Nausea / Q000139:chemically induced; D010300:Parkinson Disease / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration; D014839:Vomiting
D004295:Dihydroxyphenylalanine; D000547:Amantadine